Literature DB >> 21310923

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

Tilmann Bochtler1, Ute Hegenbart, Christiane Heiss, Axel Benner, Marion Moos, Anja Seckinger, Stephanie Pschowski-Zuck, Désirée Kirn, Kai Neben, Claus R Bartram, Anthony D Ho, Hartmut Goldschmidt, Dirk Hose, Anna Jauch, Stefan O Schonland.   

Abstract

In multiple myeloma (MM) pathogenesis, hyperdiploidy and nonhyperdiploidy are recognized as 2 major cytogenetic pathways. Here, we assessed the role of hyperdiploidy in 426 patients with monoclonal plasma cell disorders, among them 246 patients with AL amyloidosis (AL), by interphase fluorescence in situ hybridization. Hyperdiploidy was defined by a well-established score requiring trisomies for at least 2 of the 3 chromosomes 5, 9, and 15. The hyperdiploidy frequency in AL was a mere 11% compared with 30% in monoclonal gammopathy of undetermined significance (P < .001) and 46% in AL with concomitant MM I (P < .001). Overall, hyperdiploidy was associated with an intact immunoglobulin, κ light chain restriction, higher age, and bone marrow plasmacytosis, but was unrelated to the organ involvement pattern in AL. Clustering of 6 major cytogenetic aberrations in AL by an oncogenetic tree model showed that hyperdiploidy and t(11;14) were almost mutually exclusive, whereas gain of 1q21 favored hyperdiploidy. Deletion 13q14 and secondary IgH translocations were equally distributed between ploidy groups. We conclude that the interphase fluorescence in situ hybridization-based hyperdiploidy score is also a feasible tool to delineate hyperdiploid patients in early-stage monoclonal gammopathies and that the cytogenetic pathogenetic concepts developed in MM are transferable to AL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310923     DOI: 10.1182/blood-2010-02-268987

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.

Authors:  Yujia Wang; Lushuang Xu; Yang Liu; Yuzhe Hu; Qiang Shi; Lixue Jin; Lijun Yang; Pingzhang Wang; Kunshan Zhang; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

2.  Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Authors:  Tilmann Bochtler; Maximilian Merz; Thomas Hielscher; Martin Granzow; Korbinian Hoffmann; Alwin Krämer; Marc-Steffen Raab; Jens Hillengass; Anja Seckinger; Christoph Kimmich; Tobias Dittrich; Carsten Müller-Tidow; Dirk Hose; Hartmut Goldschmidt; Ute Hegenbart; Anna Jauch; Stefan O Schönland
Journal:  Blood Adv       Date:  2018-10-23

3.  Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma.

Authors:  N Weinhold; A Försti; M I da Silva Filho; J Nickel; C Campo; P Hoffmann; M M Nöthen; D Hose; H Goldschmidt; A Jauch; C Langer; U Hegenbart; S O Schönland; K Hemminki
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

4.  Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.

Authors:  Gregory P Kaufman; Angela Dispenzieri; Morie A Gertz; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Nelson Leung; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Steven R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Am J Hematol       Date:  2015-01-16       Impact factor: 10.047

5.  Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

Authors:  M I da Silva Filho; A Försti; N Weinhold; I Meziane; C Campo; S Huhn; J Nickel; P Hoffmann; M M Nöthen; K-H Jöckel; S Landi; J S Mitchell; D Johnson; G J Morgan; R Houlston; H Goldschmidt; A Jauch; P Milani; G Merlini; D Rowcieno; P Hawkins; U Hegenbart; G Palladini; A Wechalekar; S O Schönland; K Hemminki
Journal:  Leukemia       Date:  2016-12-27       Impact factor: 11.528

6.  Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.

Authors:  R Warsame; S K Kumar; M A Gertz; M Q Lacy; F K Buadi; S R Hayman; N Leung; D Dingli; J A Lust; R P Ketterling; Y Lin; S Russell; L Hwa; P Kapoor; R S Go; S R Zeldenrust; R A Kyle; S V Rajkumar; A Dispenzieri
Journal:  Blood Cancer J       Date:  2015-05-01       Impact factor: 11.037

7.  Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.

Authors:  Katharina Lisenko; Stefan O Schönland; Anna Jauch; Mindaugas Andrulis; Christoph Röcken; Anthony D Ho; Hartmut Goldschmidt; Ute Hegenbart; Michael Hundemer
Journal:  Cancer Med       Date:  2016-04-25       Impact factor: 4.452

8.  Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.

Authors:  Seok Jin Kim; Hyun-Tae Shin; Hae-Ock Lee; Nayoung K D Kim; Jae Won Yun; Jee Hyang Hwang; Kihyun Kim; Woong-Yang Park
Journal:  Oncotarget       Date:  2016-10-18

9.  Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Authors:  Martin Granzow; Ute Hegenbart; Katrin Hinderhofer; Dirk Hose; Anja Seckinger; Tilmann Bochtler; Kari Hemminki; Hartmut Goldschmidt; Stefan O Schönland; Anna Jauch
Journal:  Haematologica       Date:  2017-03-24       Impact factor: 9.941

Review 10.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.